Sign In
Buy XERS
$5.89
-0.110 (-1.83%)
At Close: Jun 03, 2026
New Research Partnership With Horizon Therapeutics Could Be the Next Revenue Catalyst for Xeris
08:01pm, Monday, 28'th Nov 2022
Technology-based biopharma company Xeris (US:XERS) is set to boost its revenue with an upfront cash payment from a research collaboration and option agreement that was secured with mid-cap pharma Hori
Xeris (XERS), Horizon to Develop Ready-to-Use Teprotumumab
12:02pm, Thursday, 24'th Nov 2022
Xeris Biopharma (XERS) enters into a research collaboration with Horizon Therapeutics to develop a ready-to-use variant of teprotumumab to treat thyroid eye disease.
Xeris Biopharma inks research collaboration and option agreement with Horizon Therapeutics
09:26am, Wednesday, 23'rd Nov 2022
Xeris Biopharma Holdings (NASDAQ:XERS) said it has entered into a research collaboration and option agreement with Horizon Therapeutics PLC. Under the terms of the agreement, Xeris will use its prop
Xeris Biopharma: Q3 Earnings Reveals Strong Growth And Path To Breakeven
12:15am, Saturday, 12'th Nov 2022
Xeris Biopharma reported its Q3 earnings with a beat on EPS and revenue. Xeris reported strong growth with record net product revenue rising 17% from the previous quarter. Xeris looks to be on track t
Xeris Biopharma posts record 3Q revenue as more patients utilize its treatments
10:12am, Friday, 11'th Nov 2022
Xeris Biopharma Holdings (NASDAQ:XERS) Inc has announced record third-quarter financial results and subsequently raised its 2022 year-end cash balance guidance. The company reported record net product
Xeris Biopharma Holdings, Inc. (XERS) Q3 2022 Earnings Call Transcript
11:07am, Wednesday, 09'th Nov 2022
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q3 2022 Earnings Conference Call November 9, 2022 8:30 AM ET Company Participants Allison Wey - Senior Vice President, Investor Relations and Corporate Co
Xeris Biopharma reveals Phase 3 SONICS study data evaluating Recorlev for Cushing's syndrome
10:51am, Tuesday, 01'st Nov 2022
Xeris Biopharma Holdings (NASDAQ:XERS) Inc revealed the results of the extended evaluation of levoketoconazole, or Recorlev, from the Phase 3 SONICS study published in the European Journal of Endocrin
Best Penny Stocks To Buy? 5 Biotech Stocks For Your Watch List This Week
02:13pm, Monday, 24'th Oct 2022
Biotech penny stocks for your watch list this week. The post Best Penny Stocks To Buy?
Xeris Biopharma reports positive topline results from Phase 1 trial of subcutaneous levothyroxine
10:15am, Thursday, 20'th Oct 2022
Xeris Biopharma Holdings Inc (NASDAQ:XERS) has announced positive topline results from its Phase 1 study of subcutaneous (SC) levothyroxine (XP-8121) in healthy adult volunteers. Using its XeriSol t
CHICAGO--(BUSINESS WIRE)-- #GvokeHypoPen--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializ
Xeris Biopharma (XERS) Upgraded to Buy: Here's What You Should Know
01:33pm, Monday, 05'th Sep 2022
Xeris Biopharma (XERS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Xeris Biopharma posts record $25.3M 2Q revenue as commercial product sales take off
02:39pm, Wednesday, 10'th Aug 2022
Xeris Biopharma Inc has announced its second-quarter financial results, revealing record net revenue of $25.3 million. The record figure represents a 15% increase from the first quarter and a 34% incr
Xeris Biopharma Holdings, Inc. (XERS) CEO Paul Edick on Q2 2022 Results - Earnings Call Transcript
09:57am, Wednesday, 10'th Aug 2022
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS ) Q2 2022 Earnings Conference Call August 10, 2022 8:30 AM ET Company Participants Allison Wey - Senior Vice President of Investor Relations and Corporate C
Xeris Biopharma Holdings (NASDAQ:XERS) Inc has noted that Tetris Pharma - its commercialization partner for Ogluo in the UK, EEA, and Switzerland - is to be acquired by Arecor Therapeutics PLC (AIM:AR
Xeris Biopharma: Q1 Earnings Reveal Path To Breakeven
12:09am, Saturday, 21'st May 2022
Xeris recently reported encouraging Q1 earnings. The company's commercial products are off to a strong start, including their recently launched product, Recorlev. Xeris reaffirmed its full-year net pr
